Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Newsroom
Press Releases
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
19/03/2024
ASIT Boston – 2024 | A Tolerizing APC-Targeted Vaccibody Vaccine Ameliorates Disease in Mouse Models of Experimental Autoimmune Encephalomyelitis and Non-Obese Diabetes
31/10/2023
SITC – 2023 | Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab
12/10/2023
RNA Cancer Vaccines Summit – 2023 | Antigen presenting cell targeted vaccines
02/10/2023
AACR Special Conference on Tumor Immunology and Immunotherapy – 2023 | High-throughput TCR sequencing demonstrates induction of long-lasting HPV16-specific T-cell responses in VB10.16 vaccinated advanced cervical cancer patients
18/04/2023
AACR – 2023 | Poster ID: CT274 | Individualized APC targeted VB10.NEO cancer vaccines induce broad neoantigen-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: Interim results from a phase 1/2a trial
Pages:
1
2
3
4
5
6
7
8
9
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
